Latest Tenofovir Stories
The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis (PrEP) can be implemented on a large scale.
A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests research presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI).
In the first study to make head-to-head comparisons between tenofovir gel and oral tenofovir â€“ two promising approaches for preventing HIV in women â€“ researchers found that daily use of the vaginal gel achieved a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet, while, compared to the gel, the tablet used daily was associated with a 20-times higher active drug concentration in blood.
A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum.
PITTSBURGH, Jan. 27, 2011 /PRNewswire/ -- Mylan Inc.
CORK, Ireland, Jan.
WASHINGTON, Dec. 23, 2010 /PRNewswire-USNewswire/ -- On December 17, Science Magazine recognized a promising HIV study as one of the top ten achievements of 2010.
Earlier initiation of antiretroviral therapy should be the highest priority for global expansion of HIV patient care.
DURHAM, N.C., Dec. 13, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile.
CONRAD is pleased to join in congratulating the Global iPrEx study team for their successful trial of oral tenofovir (TDF) with emtricitabine (FTC) for HIV prevention.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.